Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 13/20 | 0.33 |
| ▸ | RXRB | P28702 | 10/20 | 0.33 |
| ▸ | RARB | P10826 | 9/20 | 0.33 |
| ▸ | RARG | P13631 | 8/20 | 0.33 |
| ▸ | RXRG | P48443 | 6/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 6/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.31 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28996984 | 0.92 | RARB (0.30) | RXRARXRBRARBRARGRXRG | |
| SCHEMBL4436755 | 0.86 | — | — | |
| SCHEMBL5634994 | 0.77 | — | — | |
| SCHEMBL816209 | 0.77 | — | — | |
| SCHEMBL8558266 | 0.74 | KDM1A (0.34) | RXRARXRBRXRG | |
| SCHEMBL1450895 | 0.72 | RARB (0.40) | RARBRARGRARA | |
| SCHEMBL4295447 | 0.72 | RARG (0.32) | RARG | |
| SCHEMBL7223452 | 0.72 | RARA (0.39) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL9192247 | 0.72 | RARA (0.37) | RXRARARBRARGRARACYP26A1 | |
| SCHEMBL9856646 | 0.72 | RARB (0.40) | RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044216-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | University of Washington through its Center for Commercialization (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015026990-A2 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROLASE | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-02-26 | — | — | WO | claimed |
| WO-2012130306-A1 | BICYCLIC 2,3-DIHYRDOBENZAZINE COMPOUNDS FOR USE IN THERAPY | ELARA PHARMACEUTICALS GMBH (DE) | 2012-10-04 | — | — | WO | claimed |
| US-7820704-B2 | Substituted heteroaryl derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | claimed |
| US-7402576-B2 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2008-07-22 | — | — | US | claimed |
| EP-1599487-B1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2007-07-11 | — | — | EP | claimed |
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | MABIRE DOMINIQUE | 2007-05-10 | — | — | US | claimed |
| EP-1753735-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | Transtech Pharma, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GIVAUDAN SA (CH) | 2006-03-09 | — | — | US | claimed |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-11-24 | — | — | US | claimed |
| WO-2005103022-A1 | SUBSTITUTED THIAZOLE AND PYRIMIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR MODULATORS | TRANSTECH PHARMA, INC. (US) | 2005-11-03 | — | — | WO | claimed |
| WO-2004048394-A1 | PHOSPHINIC ACID ANALOGS OF GLUTAMATE | GIVAUDAN SA (CH) | 2004-06-10 | — | — | WO | claimed |
| US-5767278-A | ANTICARCINOGENIC AGENTS | GERON CORPORATION (US) | 1998-06-16 | — | — | US | claimed |
| EP-0337689-B1 | TETRALIN ESTERS OF PHENOLS OR BENZOIC ACIDS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1993-03-10 | — | — | EP | claimed |
| US-11952481-B2 | Heterophasic polypropylene composition with high flexibility and softness | BOREALIS AG (AT) | 2024-04-09 | — | — | US | disclosed |
| US-11702487-B2 | Process for preparing propylene polymers | BOREALIS AG (AT) | 2023-07-18 | — | — | US | disclosed |
| US-11078304-B2 | Process for preparing heterophasic propylene copolymers | BOREALIS AG (AT) | 2021-08-03 | — | — | US | disclosed |
| EP-0337689-A1 | Tetralin esters of phenols or benzoic acids having retinoid like activity | ALLERGAN, INC (US) | 1989-10-18 | — | — | EP | disclosed |
| EP-0176034-B1 | DIARYL ACETYLENES, THEIR PREPARATION AND USE | BASF Aktiengesellschaft (DE) | 1989-08-30 | — | — | EP | disclosed |
| EP-0263492-A1 | Retinoids, their preparation and use as pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 1988-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105858-A1 | RETINOIC ACID MIMETIC ANILIDES | RXRA, RXRB, RXRG | RXRA 1/4885RXRB 2/4885RARB 5/4885 |
| US-20060052616-A1 | Phosphinic acid analogs of glutamate | GLUL, GRIA1, GRM1 | RXRA 2713/4885RXRB 2740/4885RARB 661/4885 |
| US-20050261294-A1 | Substituted heteroaryl derivatives, compositions, and methods of use | MC5R, MC3R, MC4R | RXRA 602/4885RXRB 448/4885RARB 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.